Fantasy Football - Footballguys Forums
Welcome to Our Forums. Once you've registered and logged in, you're primed to talk football, among other topics, with the sharpest and most experienced fantasy players on the internet.
Stock Thread (7 Viewers)
- Thread starter St. Louis Bob
- Start date
Shula-holic
Footballguy
Well that didn't take long
sporthenry
Footballguy
Those things are nothing burgers. I've seen them in any stock that drops 20-30% on news and it never impacts the company, assuming it's a legit company. Won't impact much.
This notice may constitute attorney advertising.
Jayrok
Footballguy
Who wasn't expecting a couple of these? Every time a hit article comes out, these types of ambulance chasers see if they can get any chance to nibble on some scraps. Probably all part of the process.
Short stock
publish article
create panic selling
buy to cover
Notify securities ambulance chasers to broadcast potential investigations
Rinse and repeat
This happened in May as well. Didn't keep buyers away for long.
There was one earlier this year. It’s basically like seeing the injury law ada on the side of the road. I saw them on ZM after a drop when the stock was at all time highs. They are not an impact at all.
matuski
Footballguy
You see these a hundred times a day.
Sand
Footballguy
Well folks, looks like we dropped back to the price this hit last Thursday.
Oh, the humanity.
I agree with the article above that the value of this is going to be set by the trial results. Today was playing games while we wait for those. I am under no illusions this is anything but a lottery ticket, but I'm holding mine for now.
I am officially not looking at my brokerage this afternoon, though. I'm just going to pretend today didn't exist.
Oh, the humanity.
I agree with the article above that the value of this is going to be set by the trial results. Today was playing games while we wait for those. I am under no illusions this is anything but a lottery ticket, but I'm holding mine for now.
I am officially not looking at my brokerage this afternoon, though. I'm just going to pretend today didn't exist.
Warrior
Footballguy
eaganwildcats
Footballguy
How many shares does one need to get added to this distro?
chet
Footballguy
My friend sends it to me. He says it's from an sell side institutional desk but I think he's mistaken. I will post it here when i get it.
Sputnikv8
Footballguy
I saw the same blurb in the yahoo finance, cydy, "conversation" section. Posted by "Thoughtful Investing"
fyi
bshell27
Footballguy
Last edited by a moderator:
bshell27
Footballguy
VWAP is still $7. This has to run up to at least that number, no?
Also, ask is 7.90 and bid is 4. Any significance to this? Ask after close last night was 9.27 and it opened at 9.66.
I don't know what the heck is going on, but are we looking at a bounce back tomorrow? Chet's guy sure seems to think so.
Also, ask is 7.90 and bid is 4. Any significance to this? Ask after close last night was 9.27 and it opened at 9.66.
I don't know what the heck is going on, but are we looking at a bounce back tomorrow? Chet's guy sure seems to think so.
Last edited by a moderator:
chet
Footballguy
Personally, I think it will take some time to revisit 9+. I hope I am wrong. I wouldn't pay any attention to the after market bid/ask spread. The German price is interesting but it's also on very low volume.
Todem
Footballguy
Keep investing in those type of stocks.
Be willing to lose whatever you put into a stock like CYDY. And you will be fine. And know when you at least double your money....take your risk off the table and ride a free roll with the rest.
It’s like Vegas (when you play in the waters of a CYDY or similar low priced bio-tech stocks).....I go there once a year and am willing to lose the 4K I bring with me for 3 nights of fun, shooting dice. If I leave with my 4K? I won. If I make some money....awesome. If I lose all of it...but had a great time? That was the cost of entertainment and I was willing to lose it all.
Last edited by a moderator:
-OZ-
Footballguy
Tomorrow morning I calculate our end of quarter statement. But then I'll stop watching most accounts for another 92 days.I am officially not looking at my brokerage this afternoon, though. I'm just going to pretend today didn't exist.
Bob Sacamano
Footballguy
Somebody said they were selling SE. Why? Seems like the kind of stock you hold for the next 10 years with the potential for a 5x+
Bluto Blutarsky
Footballguy
TOOL’s song The Patient has become my mantra with holding CYDY. 
Last edited by a moderator:
ManOfSteelhead
Footballguy
It is quite clear they use a comma when you are down > $1,000, that is for sure....Well folks, looks like we dropped back to the price this hit last Thursday.
Oh, the humanity.
I agree with the article above that the value of this is going to be set by the trial results. Today was playing games while we wait for those. I am under no illusions this is anything but a lottery ticket, but I'm holding mine for now.
I am officially not looking at my brokerage this afternoon, though. I'm just going to pretend today didn't exist.
Bob Sacamano
Footballguy
Teaching kids (14) about investing - what you got? Any good resources? I feel like I can do it from scratch, but if I don't HAVE to...
He got some big headlines a few months ago going after Inovio after their COVID "vaccine" rocketed their stock up. Some will argue these types of people perform a valuable service pushing back against the pumpers and the Jordan Belforts of the world. IMO, most of these guys are just the same kind of scum on the other side of the coin willing to go to great lengths to torpedo any company that comes up on their radar. Sometimes they strike gold by attacking a company that was all hype or even doing things illegally or shady which gives them even more power, but they don't seem to discriminate on who they go after most of the time whether its a legit company or not.Quote
Polonium2 hours ago
"Citron launched 51 investigative reports against S&P 500 companies, between 2009 and 2015, as well as several Chinese companies, citing allegations of pyramid schemes, ineffective products and accounting, or business frauds.[7] In 2016, the founder Andrew Left was banned for five years by the Hong Kong Market Misconduct Tribunal for disclosing false or misleading information, and so inducing transactions under the Securities and Futures Ordinance.[8][9] Despite being sued by multiple companies for the reports he has released, Left claims he has never lost a case in the United States;[5][10] the National Futures Association sanctioned Left and stated that he “made false and misleading statements to cheat, defraud or deceive a customer in violation of NFA compliance rules.”[11][12]. Left, was also banned in 2016 after he was found culpable of market misconduct in connection with the publication of a research report on Chinese property developer China Evergrande Group.[13]"
This guy spread doubts about GILEAD, TESLA and so forth in the past.
Yahoo conversation.
I am not winning with CYDY in the same fashion as most of y'all. I keep buying/selling. But I have still tripled+ my money now... here's to another double up this time.
I think it should be illegal to publish "research" if you have a position in a stock either way, but the world has decided that as long as you don't outright lie and you disclose whether you are long or short it's perfectly fine. Caveat emptor.
dkp993
Footballguy
If you do can I join the class? I seem to do better with these things being explained to me like I’m 14.
Last edited by a moderator:
matuski
Footballguy
I gave each of my kids $300 in exchange for reducing their allowance by half for the year.
One put it all into Bank of America. (apparently came up in a google search).
Other is sitting on the cash, can't decide between Microsoft and Blizzard.
I am giving no input on stock picking, but reviewing every couple weeks and explaining.
Last edited by a moderator:
Charlie Harper
Footballguy
That was me. Sold my shares for a slight profit to go all in on CYDY. That turned out well!
My ####ty logic...SE seems to have stabilized right now around $105-$110. In 2 weeks we'll find out if CYDY is legit or not. I'm willing to chase the upside of CYDY.
Also, I saw an article on chasing alpha from end of May that said SE might be cooking the books. It was behind a paywall so I didn't read it, but it was just enough to put some doubt in the stock.
Again my whole self managed gambling portfolio is only $10k and I've been only been doing this since April. So feel free to just laugh at me.
-OZ-
Footballguy
Agreed. Definitely among my Titans. Rebalancing tomorrow, I actually boosted it up from 8% to 10% of my IRA. So it won't sell any.
Otoh, I must admit I'm selling a little of my Tesla. Just back to the target 8%, it too had grown to just under 10%. Most of that will go to Disney shares which have underperformed.
-OZ-
Footballguy
matuski
Footballguy
I am not a big winner like the CYDY OG's, but I wanted to thank this thread. 
I turned $35k that was sitting earning whatever 1% ish interest rate ... into $60k+ over the last few months. @Todem, @chet (I know chet doesn't like me hah), @FreeBaGeL... thanks. Others obviously, but in particular these guys have served me well.
Never even occurred to me to invest/trade with this money before. Wish I had been here years earlier, that 35k had just been sitting there growing by the few hundred/month I had forgottenly set to automatic transfer
I had literally forgotten this account existed beyond that it was a pseudo rainy day backup.
It has been fun and eye opening.
I turned $35k that was sitting earning whatever 1% ish interest rate ... into $60k+ over the last few months. @Todem, @chet (I know chet doesn't like me hah), @FreeBaGeL... thanks. Others obviously, but in particular these guys have served me well.
Never even occurred to me to invest/trade with this money before. Wish I had been here years earlier, that 35k had just been sitting there growing by the few hundred/month I had forgottenly set to automatic transfer
I had literally forgotten this account existed beyond that it was a pseudo rainy day backup.It has been fun and eye opening.
Last edited by a moderator:
Judge Smails
Footballguy
Took down from Citron but this was what it was. Sorry if honda
CytoDyn (CYDY)
SEC Must Immediately Halt this Stock Promotion Scheme
We cannot remember the last time we’ve seen a bigger joke of a stock. This is a
$5 billion market cap company with 10 employees who claims to have the cure
for COVID with zero data and a CEO who sold >$30 million of stock ~70% lower
than yesterday’s closing stock price.
The CEO has made inappropriate promotional claims like “this looks the solution
to coronavirus” leading into his most recent stock sale.
On Feb 4th, 2020, the SEC issued an Investor Alert warning about COVID-related
stock promotions. CytoDyn, a Vancouver based OTC-listed biotech company,
appears to be one such stock promotion. The brazen stock promotion scheme
should immediately be halted by the SEC.
Culper Research has also done good work here which covers the history of the
company in more detail.
https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_2-6-
2020.pdf?ver=1591103388830
https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_2-12-
2020.pdf?ver=1591103388830
https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_5-8-
2020.pdf?ver=1591103388830
CytoDyn has aggressively touted its investigational drug candidate, Leronlimab, as
a potential treatment for COVID-19. However, there is zero scientific data to
support this view. This has not prevented the company from making several
misleading and disingenuous claims in an effort to generate hype around their
drug candidate and stock price.
So far this year, CytoDyn has issued 51 press releases, conducted 5 conference
calls, participated in no less than 24 interviews, and has utilized several third-
party investor relations and stock newsletter services.
CytoDyn has used the increased attention to raise capital multiple times since
January 2020. The company has regularly employed selective and incomplete
disclosure in order to continue to promote the stock.
Page 2
June 30, 2020
© Copyright 2020 | Citron Research | www.citronresearch.com | All Inquiries – info@citronresearch.com
Below are the red flags that should be on the radar of the SEC:
• On April 27, 2020, CytoDyn held its latest investor conference call. Jacob
Lalezari, the company’s interim Chief Medical Officer (CMO) made several
statements implying Leronlimab’s efficacy in treating patients with COVID.
Not only are these claims highly inappropriate given the lack of available
data, Lalezari was presented as an independent medical authority with no
financial interest in CytoDyn
o “It’s clear this drug is working, working better than we ever could
have imagined. The sooner we bring relief to people, the better”
o “I think we’ve shown this could be the one drug that does it all”
o “There’s no doubt in my mind anymore about how important this
drug is going to be for COVID-19”
• On the same conference call, CEO Nader Pourhassan said that he believed
his mother-in-law was alive because of Leronlimab treatment. Though the
Leronlimab trial received clearance in Nov 2018 and expects to enroll 48
patients, enrollment thus far has been just 3, of which 1 is the CEO’s
mother-in-law
o In the absence of real clinical data, the company relies on buzzy
anecdotal reports and makes grandiose claims such as “the patient is
somebody close to me, in San Jose. This patient was … essentially
[on] life support … and is now close to being off ventilator and
they’ve already made plans to ship her to rehab to continue her
care and physical therapy” (2:36, Apr 30th, 2020 Proactive Investors)
• Prior to the April 27 call, the COVID-19 thesis put forth by management was
that Leronlimab would aid in supressing the cytokine storm which has been
leading to complications in many cases. Before this point, Leronlimab was
not framed as anti-viral. On April 24, a letter to the editor was published in
the NEJM that included data from Kidney-transplant recipients that had
been infected with COVID-19. 6 of 36 patients were administered
Leronlimab. Only 1 those patients remained in stable condition without
intubation. CytoDyn management failed to mention this important fact on
their April 27 call despite indicating that the NEJM publication was one of
the subjects of the call. They did briefly mention the reduction in IL-6 levels
in treated patients, but failed to mention the clinical outcomes. Instead,
the company pivoted its thesis and claimed that Leronlimab has been
associated with reduction in viral load observed in blood plasma. This
appears to be a bait and switch whereby management is attempting to
avoid disclosing any negative information to investors. When asked to
Page 3
June 30, 2020
© Copyright 2020 | Citron Research | www.citronresearch.com | All Inquiries – info@citronresearch.com
elaborate on their new breakthrough by a participant on the call, the CEO
refuses to provide any additional detail and ends the Q&A shortly
thereafter
o On April 27, Sanofi / Regeneron announced disappointing results
from their phase 2 trial testing Kevzara (an IL-6 inhibitor) on COVID-
19 patients. This has potential read-through to CytoDyn’s original
hopes for Leronlimab, which is likely another reason the company
decided to pivot away from their original thesis
o CytoDyn’s March 16 press release indicates Leronlimab is being
explored as “therapy for patients who experience respiratory
complications” from COVID-19. There is no mention of anti-viral
properties at any point before the April 27 call
• While CytoDyn continues to avoid disseminating any negative news to
investors, the company never wastes an opportunity to tout anecdotal
COVID-19 success stories. This selective disclosure is alarming because it
fails to portray an accurate picture to investors. To-date the company has
not disclosed full data from the patients they have treated
o “patients with mild-moderate disease were given a dose of
leronlimab, they very quickly come off oxygen. We have many
patients now who were intubated, they were given a dose of
leronlimab, they come off intubation” (6:29, Apr 13th, 2020 Proactive
Investors)
o In response to why the HIV BLA hasn’t yet been submitted: “saving
these peoples lives today is the most urgent thing we could be doing
… we said “ok lets try it” and so we had to put all of our team to save
peoples lives. Thank you, the shareholders, for allowing the company
to be at this point to be able to do that. So we saved some lives, its
been on the news, it’s no fluke or hoax, it happened” (4:11). “For the
good of the humanity we’re going to try it and now it looks like, to
me, that this is the solution to coronavirus” (5:30, Apr 15th,
2020 Proactive Investors)
o “at the end of the day that [offering some ray of hope to help save
the lives of loved ones] is what keeps CytoDyn working, it’s always
been a company with huge heart and a major focus on patients and
it’s also something that keeps us working long hours in the lab to
figure this disease out, and I think we have … the results explain
themselves” (8:05, Apr 30th, 2020 Proactive Investors)
• The company has stated several times that it recently raised capital in the
form of debt convertible into stock at $4.50 per share with no warrants.
Page 4
June 30, 2020
© Copyright 2020 | Citron Research | www.citronresearch.com | All Inquiries – info@citronresearch.com
The company has attempted to frame this as validation of their success –
the supposed ability to raise external capital at favorable terms. However,
what CytoDyn fails to mention is that the convertible note has a reset
feature – its conversion price gets adjusted down to wherever the
company’s next equity deal gets priced. As a result, the sticker price of the
convertible financing is largely irrelevant. Furthermore, the financing
included an original issuer discount (OID) of $2.1 million, representing ~12%
of the total principal amount of the financing. Iliad Research and Trading
has a history of financing questionable public microcap entities with similar
structured financings
• On April 28, 2020, CytoDyn disclosed that shareholders, including three
former Board Members, had filed a lawsuit against CytoDyn for unjust
enrichment. The three former Board Members include Anthony Caracciolo
(2012-2019), Greg Gould (2007-2019), and Carl Dockery (2014-2019),
where all three resigned in 2019. Part of the complaint is related to a
contingent share award disclosed on January 28, 2020 whereby
management was to be granted 11.65m shares (currently worth >US$30m)
if CytoDyn achieves breakthrough designation within 6 months. The value
of this award is egregious relative to the milestone involved and the pre-
revenue nature of the company. This award supports the view that
CytoDyn is a stock promotion scheme intended to enrich insiders
• Days later, on Apr 30th, 2020, CytoDyn filed an S-3/A which includes 2
million $0.63 warrants issued to CEO Nader Pourhassan in connection
with the above-mentioned share grant S-3/A. The S-3 also listed Michael
McCarthy from the Dream Team Group, a former stock promotion scheme
exposed by Adam Feuerstein and Richard Pearson Buysstrike
• CEO Nader Pourhassan ultimately sold ~10 million shares (>$30 million)
between Apr 30th and May 4th
• There is an alarming level of management and board turnover as well as
troubling allegations that the CEO has ignored concerns around patient
safety from the company’s former CMO. This struggle resulted in three
additional board member resignations and was well-highlighted in a lawsuit
filed by the same CMO (lawsuit number: 1:19-cv-01563-RGA). Several of
these resigned board members are involved in the above-referenced unjust
enrichment lawsuit
CytoDyn (CYDY)
SEC Must Immediately Halt this Stock Promotion Scheme
We cannot remember the last time we’ve seen a bigger joke of a stock. This is a
$5 billion market cap company with 10 employees who claims to have the cure
for COVID with zero data and a CEO who sold >$30 million of stock ~70% lower
than yesterday’s closing stock price.
The CEO has made inappropriate promotional claims like “this looks the solution
to coronavirus” leading into his most recent stock sale.
On Feb 4th, 2020, the SEC issued an Investor Alert warning about COVID-related
stock promotions. CytoDyn, a Vancouver based OTC-listed biotech company,
appears to be one such stock promotion. The brazen stock promotion scheme
should immediately be halted by the SEC.
Culper Research has also done good work here which covers the history of the
company in more detail.
https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_2-6-
2020.pdf?ver=1591103388830
https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_2-12-
2020.pdf?ver=1591103388830
https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_5-8-
2020.pdf?ver=1591103388830
CytoDyn has aggressively touted its investigational drug candidate, Leronlimab, as
a potential treatment for COVID-19. However, there is zero scientific data to
support this view. This has not prevented the company from making several
misleading and disingenuous claims in an effort to generate hype around their
drug candidate and stock price.
So far this year, CytoDyn has issued 51 press releases, conducted 5 conference
calls, participated in no less than 24 interviews, and has utilized several third-
party investor relations and stock newsletter services.
CytoDyn has used the increased attention to raise capital multiple times since
January 2020. The company has regularly employed selective and incomplete
disclosure in order to continue to promote the stock.
Page 2
June 30, 2020
© Copyright 2020 | Citron Research | www.citronresearch.com | All Inquiries – info@citronresearch.com
Below are the red flags that should be on the radar of the SEC:
• On April 27, 2020, CytoDyn held its latest investor conference call. Jacob
Lalezari, the company’s interim Chief Medical Officer (CMO) made several
statements implying Leronlimab’s efficacy in treating patients with COVID.
Not only are these claims highly inappropriate given the lack of available
data, Lalezari was presented as an independent medical authority with no
financial interest in CytoDyn
o “It’s clear this drug is working, working better than we ever could
have imagined. The sooner we bring relief to people, the better”
o “I think we’ve shown this could be the one drug that does it all”
o “There’s no doubt in my mind anymore about how important this
drug is going to be for COVID-19”
• On the same conference call, CEO Nader Pourhassan said that he believed
his mother-in-law was alive because of Leronlimab treatment. Though the
Leronlimab trial received clearance in Nov 2018 and expects to enroll 48
patients, enrollment thus far has been just 3, of which 1 is the CEO’s
mother-in-law
o In the absence of real clinical data, the company relies on buzzy
anecdotal reports and makes grandiose claims such as “the patient is
somebody close to me, in San Jose. This patient was … essentially
[on] life support … and is now close to being off ventilator and
they’ve already made plans to ship her to rehab to continue her
care and physical therapy” (2:36, Apr 30th, 2020 Proactive Investors)
• Prior to the April 27 call, the COVID-19 thesis put forth by management was
that Leronlimab would aid in supressing the cytokine storm which has been
leading to complications in many cases. Before this point, Leronlimab was
not framed as anti-viral. On April 24, a letter to the editor was published in
the NEJM that included data from Kidney-transplant recipients that had
been infected with COVID-19. 6 of 36 patients were administered
Leronlimab. Only 1 those patients remained in stable condition without
intubation. CytoDyn management failed to mention this important fact on
their April 27 call despite indicating that the NEJM publication was one of
the subjects of the call. They did briefly mention the reduction in IL-6 levels
in treated patients, but failed to mention the clinical outcomes. Instead,
the company pivoted its thesis and claimed that Leronlimab has been
associated with reduction in viral load observed in blood plasma. This
appears to be a bait and switch whereby management is attempting to
avoid disclosing any negative information to investors. When asked to
Page 3
June 30, 2020
© Copyright 2020 | Citron Research | www.citronresearch.com | All Inquiries – info@citronresearch.com
elaborate on their new breakthrough by a participant on the call, the CEO
refuses to provide any additional detail and ends the Q&A shortly
thereafter
o On April 27, Sanofi / Regeneron announced disappointing results
from their phase 2 trial testing Kevzara (an IL-6 inhibitor) on COVID-
19 patients. This has potential read-through to CytoDyn’s original
hopes for Leronlimab, which is likely another reason the company
decided to pivot away from their original thesis
o CytoDyn’s March 16 press release indicates Leronlimab is being
explored as “therapy for patients who experience respiratory
complications” from COVID-19. There is no mention of anti-viral
properties at any point before the April 27 call
• While CytoDyn continues to avoid disseminating any negative news to
investors, the company never wastes an opportunity to tout anecdotal
COVID-19 success stories. This selective disclosure is alarming because it
fails to portray an accurate picture to investors. To-date the company has
not disclosed full data from the patients they have treated
o “patients with mild-moderate disease were given a dose of
leronlimab, they very quickly come off oxygen. We have many
patients now who were intubated, they were given a dose of
leronlimab, they come off intubation” (6:29, Apr 13th, 2020 Proactive
Investors)
o In response to why the HIV BLA hasn’t yet been submitted: “saving
these peoples lives today is the most urgent thing we could be doing
… we said “ok lets try it” and so we had to put all of our team to save
peoples lives. Thank you, the shareholders, for allowing the company
to be at this point to be able to do that. So we saved some lives, its
been on the news, it’s no fluke or hoax, it happened” (4:11). “For the
good of the humanity we’re going to try it and now it looks like, to
me, that this is the solution to coronavirus” (5:30, Apr 15th,
2020 Proactive Investors)
o “at the end of the day that [offering some ray of hope to help save
the lives of loved ones] is what keeps CytoDyn working, it’s always
been a company with huge heart and a major focus on patients and
it’s also something that keeps us working long hours in the lab to
figure this disease out, and I think we have … the results explain
themselves” (8:05, Apr 30th, 2020 Proactive Investors)
• The company has stated several times that it recently raised capital in the
form of debt convertible into stock at $4.50 per share with no warrants.
Page 4
June 30, 2020
© Copyright 2020 | Citron Research | www.citronresearch.com | All Inquiries – info@citronresearch.com
The company has attempted to frame this as validation of their success –
the supposed ability to raise external capital at favorable terms. However,
what CytoDyn fails to mention is that the convertible note has a reset
feature – its conversion price gets adjusted down to wherever the
company’s next equity deal gets priced. As a result, the sticker price of the
convertible financing is largely irrelevant. Furthermore, the financing
included an original issuer discount (OID) of $2.1 million, representing ~12%
of the total principal amount of the financing. Iliad Research and Trading
has a history of financing questionable public microcap entities with similar
structured financings
• On April 28, 2020, CytoDyn disclosed that shareholders, including three
former Board Members, had filed a lawsuit against CytoDyn for unjust
enrichment. The three former Board Members include Anthony Caracciolo
(2012-2019), Greg Gould (2007-2019), and Carl Dockery (2014-2019),
where all three resigned in 2019. Part of the complaint is related to a
contingent share award disclosed on January 28, 2020 whereby
management was to be granted 11.65m shares (currently worth >US$30m)
if CytoDyn achieves breakthrough designation within 6 months. The value
of this award is egregious relative to the milestone involved and the pre-
revenue nature of the company. This award supports the view that
CytoDyn is a stock promotion scheme intended to enrich insiders
• Days later, on Apr 30th, 2020, CytoDyn filed an S-3/A which includes 2
million $0.63 warrants issued to CEO Nader Pourhassan in connection
with the above-mentioned share grant S-3/A. The S-3 also listed Michael
McCarthy from the Dream Team Group, a former stock promotion scheme
exposed by Adam Feuerstein and Richard Pearson Buysstrike
• CEO Nader Pourhassan ultimately sold ~10 million shares (>$30 million)
between Apr 30th and May 4th
• There is an alarming level of management and board turnover as well as
troubling allegations that the CEO has ignored concerns around patient
safety from the company’s former CMO. This struggle resulted in three
additional board member resignations and was well-highlighted in a lawsuit
filed by the same CMO (lawsuit number: 1:19-cv-01563-RGA). Several of
these resigned board members are involved in the above-referenced unjust
enrichment lawsuit
sporthenry
Footballguy
It's not unheard of for companies to respond to these reports with press releases of their own. If they want to get ahead of it and state their own case. No idea if they're in a blackout period related to the data.
TripItUp
Footballguy
which is why my advice was to lock in solid gains when people were getting 3X or better.
Zegras11
Footballguy
Last edited by a moderator:
NajehHejan
Footballguy
Anyone who’s smart at this investing stuff - could use some perspective/help
I’m researching international stock ETF that pay a dividend. To diversify all my domestic exposure but guarantee income. I found IDV. The quarterly dividend going back years is all over the map. Dividend yield shows at 7.07%. Last ex date was 6/15. How far do they go back when they calculate the dividend yield? Is it one year average of the last 4 quarters? Is it average of last full calendar year? Trying to determine how sustainable this juicy 7.07% yield is. TIA!
I’m researching international stock ETF that pay a dividend. To diversify all my domestic exposure but guarantee income. I found IDV. The quarterly dividend going back years is all over the map. Dividend yield shows at 7.07%. Last ex date was 6/15. How far do they go back when they calculate the dividend yield? Is it one year average of the last 4 quarters? Is it average of last full calendar year? Trying to determine how sustainable this juicy 7.07% yield is. TIA!
Last edited by a moderator:
Shula-holic
Footballguy
Been there before dude. Look at BLMN this way, you didn't sell at $9.66 and miss the rebuy on Friday by a few pennies only to be left at the station. I still think you'll come out ok on that. We all make mistakes. For me, most times my regrets are the trades I make too early or hastily.
One
Not Allowed In Mexico
Last edited by a moderator:
chet
Footballguy
matuski
Footballguy
I failed 2 out of 3 tries BLMN, I am 4 for 4 on CYDY.
I imagine this is why people don't do this for a living.. rolling the dice.
Shula-holic
Footballguy
It's a gamble for sure like Todem said. I only really worry when I'm not a super long term holder. The stuff I want to own for 10+ years I don't really care if they bounce around. Sometimes I hope for it to add more. I've been taking the winnings from the gambles to accumulate the long term stuff rather than raise the stakes in the gambling.
